For medical cannabis patients, drug delivery can make a huge difference in the quality of treatment. As patients look for options besides smoking dry flower or consuming edibles, oral thin strips CureFilm™ delivers active ingredients as the film dissolves inside the patient’s cheek or under the tongue.
CURE Pharmaceutical is using biotechnology to develop a more efficient way to deliver and experience cannabinoid medicines.
Patient-centric care and new development for biotechnologies are predicted as major trends in medicine for 2018 according to Health Affairs – and CURE has these covered.
CURE’s company mission, announced this month, is to support patient needs for better delivery of medication.
Robert Davidson, CEO of CURE Pharmaceutical, said there’s an “opportunity to elevate awareness around the challenges patients experience with traditional drug delivery methods, such as pills and injections and to highlight CURE’s solutions.”
“As much as 40 percent of the population struggle to swallow pills, and when they do, can have gastrointestinal irritation and are often slow to take effect causing patients to suffer. For drugs that cannot be delivered orally, patients rely on injections and endure the associated pain and inconvenience,” Davidson said.
CureFilm™ oral thin strips have a time-release element for longer lasting treatment than traditional pills or injections, and increase bioavailability so that more active ingredients reach their target destinations in the body.
CURE is a leader in cannabis biotechnology and recently presented at the 2018 Biotech Showcase in San Francisco, CA, January 8 -10, 2018.
Davidson said, “In addition to proving our technology’s effectiveness for pharmaceuticals, we’ve also expanded our patent portfolio, forged new partnerships with cutting-edge companies looking for new methods to deliver their proprietary molecules and attracted industry veterans to join our management team and board.”
Davidson shared CURE’s focus areas for 2018 with Cashinbis.
What is CURE’s main focus area?
As a company, we’re interested in research surrounding the cannabinoid molecule and its multiple implications. We’re working with regulatory agencies and developing different treatments. When it comes to the endocannabinoid system, treatments are untapped.
What type of investors are you looking for?
We’re a public company looking for investors interested in social impact, healthcare, patient advocacy and patient care.
What game-changing technology has CURE developed?
Our new technology is being integrated from drug discovery and drug delivery technologies. We’re looking at more efficient ways of delivering molecules to the body. With encapsulation, we can encapsulate cannabinoid molecules too large to deliver by itself. The cannabinoid molecule is poised for growth in the industry.
A game-changer is the oral thin film technology, CureFilm™. We can deliver medicine fast to the blood using a buccal (through oral membranes) method. When we can take invasive therapies and instead deliver through a buccal method, it increases bioavailability with less side effects.
Why is time release an important element for medicine?
The best way to look at it is emergency medicine at an accident site. Time release medicine can deliver a portion of the active ingredient immediately – but you want it to last so the person isn’t in pain an hour later – so time release offers longer lasting treatment in less doses. It has applications for conditions like diabetes, you want to keep the actives in the system. There’s a lot of need for both immediate effect and long effect duration.
What cannabinoid research caught your attention recently?
There’s a lot of institutions and universities looking at how endocannabinoids can treat traumatic brain injury. The main research is being done with CBD, and there’s a lot of potential there.